No Data
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Agios Pharmaceuticals, Inc. (AGIO) Q3 2024 Earnings Call Transcript Summary
Agios Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Revenue Results.
Agios Pharmaceuticals | 10-Q: Quarterly report
Agios Pharmaceuticals GAAP EPS of $16.22 Beats by $7.53, Revenue of $8.96M Misses by $0.54M
Agios Pharmaceuticals: Q3 Earnings Snapshot